for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.O

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.25

 - 

6.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.47
Open
--
Volume
--
3M AVG Volume
0.00
Today's High
--
Today's Low
--
52 Week High
6.58
52 Week Low
6.25
Shares Out (MIL)
98.90
Market Cap (MIL)
639.90
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Sinovac Biotech Ltd Says Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine And Aihua Pan

Sinovac Reports Preliminary Phase I/II Results Of Covid-19 Vaccine In Elderly Volunteers

Sinovac Biotech Reports Q2 Non-GAAP Loss Per Share Of $0.04

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sinovac Biotech Ltd.

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Industry

Biotechnology & Drugs

Contact Info

39 Shangdi Xi Road, Haidian District

BEIJING, BEJ

102200

China

+86.10.82890088

http://www.sinovac.com/

Executive Leadership

WeiDong Yin

Chairman of the Board, President, Chief Executive Officer, Secretary

Nan Wang

Chief Financial Officer, Vice President

Xiaomei Yin

Vice President - Sales and Marketing

Qiang Gao

Vice President - Research and Development

Jing Li

Vice President - Quality and Production

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
3.00
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
18.42
Total Debt To Equity (MRQ)
13.46
LT Debt To Equity (MRQ)
5.82
Return on Investment (TTM)
11.09
Return on Equity (TTM)
7.68

Latest News

Latest News

Sao Paulo governor floats using Sinovac vaccine without Brasilia's approval

Sao Paulo could roll out a COVID-19 vaccine developed by China's Sinovac without approval from the national health regulator, Governor Joao Doria said in an interview on Thursday, pressuring Brasilia to greenlight the vaccine.

Sao Paulo may use Sinovac vaccine without Brazil regulator's approval, governor says

The state of Sao Paulo could roll out the COVID-19 vaccine developed by China's Sinovac even without approval from Brazil's health regulator, the state's governor said in an interview on Thursday.

Turkey announces asymptomatic coronavirus case numbers for first time since July

Turkey recorded 28,351 new coronavirus cases in the last 24 hours, including 6,814 with symptoms, Health Minister Fahrettin Koca said on Wednesday, the first time since July Ankara has included asymptomatic cases in the total.

Philippines in advanced talks with AstraZeneca for vaccine

The Philippines is close to concluding talks with Britain's AstraZeneca for the supply of at least 20 million doses of its COVID-19 vaccine, a top coronavirus task force official said on Monday.

Sinovac may get Phase III trial results of COVID-19 vaccine by Dec, executive says

Chinese vaccine maker Sinovac Biotech could have the results of its experimental COVID-19 vaccine from late-stage clinical trials as soon as next month, an executive said on Friday.

First doses of China's CoronaVac COVID-19 vaccine arrive in Brazil

The first 120,000 doses of CoronaVac, a COVID-19 vaccine developed by China's Sinovac Biotech that is being tested in Brazil, arrived at São Paulo's international airport on Thursday morning, the state government said.

Turkey to buy Chinese COVID-19 candidate vaccine doses, in talks with Pfizer

Turkey will sign a contract within days to buy at least 20 million doses of a COVID-19 candidate vaccine from China's Sinovac Biotech, the health minister was cited as saying, adding that Ankara was also in talks to buy doses of Pfizer and BioNTech's vaccine.

Sinovac's COVID-19 vaccine induces quick immune response - study

Sinovac Biotech's <SVA.O> experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.

Sinovac's COVID-19 vaccine induces quick immune response - study

Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.

Brazil trial of China's Sinovac vaccine not affected by suspension

The two-day suspension of a late-stage clinical trial in Brazil for a COVID-19 vaccine developed by China's Sinovac <SVA.O> has not impacted the study, the head of the Sao Paulo institute running the trial said on Thursday.

Suicide halts Brazil trial of Chinese vaccine attacked by Bolsonaro

Brazil's health regulator suspended a clinical trial of China's Sinovac coronavirus vaccine due to a severe adverse event, delighting President Jair Bolsonaro, who has repeatedly criticized the vaccine's credibility and said it would not be purchased by his government.

Breakingviews - Chinese vaccine developer flags corporate disease

A once-in-a-lifetime pandemic opportunity is being undermined by an equally rare corporate governance disaster. Sinovac Biotech’s Covid-19 vaccine tests were showing promising signs before hitting a snag this week. The Chinese company’s shareholders can only sit by and watch...

Chile, Peru green-light AstraZeneca COVID-19 vaccine trials

Chilean President Sebastian Pinera said on Wednesday the country's health regulator had given the go-ahead for clinical trials of AstraZeneca PLC's <AZN.L> COVID-19 vaccine.

UPDATE 1-Brazil authorizes import of raw material to produce Chinese COVID-19 vaccine

Brazil's health regulator Anvisa said on Wednesday it has authorized the import of raw materials from Chinese company Sinovac for the production of its COVID-19 vaccine.

Brazil authorizes import of raw material to produce Chinese COVID-19 vaccine

Brazil's health regulator Anvisa said on Wednesday it has authorized the import of raw materials from Chinese company Sinovac for the production of its COVID-19 vaccine.

Brazil institute to import Chinese COVID-19 vaccine rejected by Bolsonaro

Brazilian regulator Anvisa on Friday authorized a biomedical center to import 6 million doses of the Sinovac coronavirus vaccine, one day after President Jair Bolsonaro said Brazil would not buy the Chinese vaccine.

Brazil's Bolsonaro rejects plan to buy China's Sinovac vaccine; health minister tests positive

Brazil's President Jair Bolsonaro said on Wednesday the federal government will not buy a COVID-19 vaccine from China's Sinovac, one day after the health minister said it would be included in the nation's immunization program.

Brazil's Butantan Institute will produce Sinovac vaccine even if excluded from national program

Brazil's Butantan Institute will manufacture 46 million doses of the COVID-19 vaccine developed by China's Sinovac, which will be made available even if the vaccine is not included in the federal immunization program, director Dimas Covas said on Wednesday.

China's Sinovac vaccine to be included in Brazil's immunization program, governors say

The Brazilian government will include China's Sinovac <SVA.O> vaccine against COVID-19 in its national immunization program, state governors said on Tuesday after a meeting with the country's health minister, in addition to one developed by AstraZeneca <AZN.L> and Oxford...

Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60

(This October 16 story was refiled to correct spelling of city Jiaxing in 4th paragraph)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up